| Literature DB >> 21970718 |
Roberto Bruni1, Cinzia Marcantonio, Elena Tritarelli, Paola Tataseo, Emilia Stellacci, Angela Costantino, Umbertina Villano, Angela Battistini, Anna Rita Ciccaglione.
Abstract
BACKGROUND: Infections with hepatitis C virus (HCV) progress to chronic phase in 80% of patients. To date, the effect produced by HCV on the expression of microRNAs (miRs) involved in the interferon-β (IFN-β) antiviral pathway has not been explored in details. Thus, we compared the expression profile of 24 selected miRs in IFN-β-treated Huh-7 cells and in three different clones of Huh-7 cells carrying a self-replicating HCV RNA which express all viral proteins (HCV replicon system).Entities:
Mesh:
Substances:
Year: 2011 PMID: 21970718 PMCID: PMC3224138 DOI: 10.1186/1471-2164-12-485
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Fold-change of 24 selected miRs in IFNβ-treated Huh-7 and 21-5 cell lines vs. Huh-7
| Huh-7+ IFNβ | 21-5 | |
|---|---|---|
| miR-1 | ||
| miR-30a-3p | ||
| miR-146a | ||
| miR-142-5p | ||
| miR-146b | ||
| miR-142-3p | ||
| miR-296 | ||
| miR-155 | ||
| miR-128a | ||
| miR-128b | ||
| miR-196a | ||
| miR-125a | 1, 05 | |
| miR-196b | 1, 11 | |
| miR-30c | -1, 12 | |
| miR-30b | -1, 04 | |
| miR-122a | 1, 14 | |
| miR-125b | -1, 10 | 1, 19 |
| miR-30e-5p | 1, 14 | 1, 18 |
| miR-30e-3p | 1, 17 | |
| miR-30a-5p | 1, 15 | |
| miR-30d | -1, 12 | 1, 02 |
| miR-351 | n.d. | n.d. |
| miR-431 | n.d. | n.d. |
| miR-448 | n.d. | n.d. |
In bold: fold-change values > 1.2 or < -1.2
n.d.: not detected, i.e. miRs showing an expression level below the detection limit of the assay (Ct ≥ 40)
Figure 1Fold-change of 16 miRs modulated in IFN-β-treated Huh-7 cells and in 21-5 replicon cells. Total RNA from both cell lines was used to assess miR levels using real time RT-PCR. miR levels from Huh-7 cells were set as the basis for the comparative results. miRs with a fold-change > 1.2 or < -1.2 were considered differentially expressed in 21-5 vs. Huh-7 cells. The mean of three independent biological replicas ± SD is reported; the RNA extract from each biological replica had been assayed by real-time RT-PCR in triplicate (three technical replicas per each RNA extract). (A) Concordant modulation (up- or down-regulation) of 9 miRs (miR-1, miR-30a-3p, miR-142-5p, miR-142-3p, miR-146a, miR-146b, miR-155, miR-128a and miR-296) in IFN-β-treated Huh-7 cells and in 21-5 replicon cells. (B) Modulation of five miRs (miR-196b, miR-125a, miR-122a, miR-30c and miR-30b) in 21-5 replicon cells. (C) Discordant modulation of two miRs (miR-128b and miR-196a) in IFN-β-treated Huh-7 cells and in 21-5 replicon cells.
Figure 2Concordant expression of 3 miRs in different HCV replicon clones. Total RNA from 21-5, 21-7 and 22-6 replicon cell lines was used to assess the level of miR-128a, miR-196a and miR-143-3p, using real time RT-PCR. miR levels from Huh-7 cells were set as the basis for the comparative results. The mean of three independent experiments ± SD is reported.
Figure 3Venn diagram showing validation of predicted target genes by microarray analysis. Dataset 1 corresponds to the list of 1981 total target genes predicted for miR-128a, miR-196a and miR-142-3p; dataset 2 includes 676 genes differentially expressed in microarray analysis in all HCV clones as compared to Huh-7 cells. The number of predicted target genes differentially expressed in microarray analysis was 83, and 37 (44, 5%) showed an expression level inversely correlated with that of the corresponding miR.
Reverse regulatory association of 3 differentially expressed miRNAs and their 37 predicted target genes in HCV replicon clones vs. Huh-7
| Gene_Symbol | Gene_name | ProbeID | Fold-change | p-value | Biological process and Molecular function | |
|---|---|---|---|---|---|---|
| miR-128a | CAMTA1 | calmodulin binding transcription activator 1 | 164871 | 1.426 | 0.045 | Signal transduction/Calcium mediated signaling |
| miR-128a | CAST | calpastatin | 222724 | 1.788 | 0.002 | Cysteine protease inhibitor|Select regulatory molecule |
| miR-128a | CORO1C | coronin, actin binding protein, 1C | 107201 | 1.402 | 0.027 | Cytoskeletal protein|Actin binding cytoskeletal protein |
| miR-128a | PARK7 | Parkinson disease (autosomal recessive, early onset) 7 | 136848 | 1.529 | 0.003 | Nucleic acid binding |
| miR-128a | REPS1 | RALBP1 associated Eps domain containing 1 | 147893 | 1.352 | 0.002 | Intracellular protein traffic/Endocytosis |
| miR-128a | RND3# | Rho family GTPase 3 | 129829 | 2.161 | 0.041 | G-protein|Small GTPase|Select regulatory molecule |
| miR-128a | SAA4 | serum amyloid A4, constitutive | 214434 | 1.880 | 0.029 | Apolipoprotein;Defense/immunity protein |
| miR-128a | TMCC1 | transmembrane and coiled-coil domain family 1 | 112169 | 1.369 | 0.031 | unclassified |
| miR-128a | TRAPPC4 | trafficking protein particle complex 4 | 205369 | 1.502 | 0.012 | Membrane traffic protein |
| miR-128a | UBE2E3 | ubiquitin-conjugating enzyme E2E 3 (UBC4/5 homolog, yeast) | 201108 | 1.505 | 0.030 | Ligase|Other ligase |
| miR-128a | VAMP8 | vesicle-associated membrane protein 8 (endobrevin) | 226943 | 2.586 | 0.011 | SNARE protein|Membrane traffic protein |
| miR-196a | ARMET | arginine-rich, mutated in early stage tumors | 144765 | 1.816 | 0.029 | unclassified |
| miR-196a | HADH2 | hydroxyacyl-Coenzyme A dehydrogenase, type II | 142475 | 1.421 | 0.031 | Oxidoreductase|Reductase|Dehydrogenase;Oxidoreductase |
| miR-196a | HIST1H2BD | histone 1, H2bd | 148940 | 2.656 | 0.020 | DNA binding |
| miR-196a | HNMT▲ | histamine N-methyltransferase | 227509 | 1.423 | 0.039 | unclassified|IRG▲ |
| miR-196a | LAMA4 | laminin, alpha 4 | 101059 | 2.660 | 0.033 | Extracellular matrix|Extracellular matrix linker protein |
| miR-196a | LTB4DH# | leukotriene B4 12-hydroxydehydrogenase | 210882 | 1.961 | 0.001 | Oxidoreductase|Reductase|Dehydrogenase;Oxidoreductase |
| miR-196a | PI3 | peptidase inhibitor 3, skin-derived (SKALP) | 128827 | 2.558 | 0.018 | Proteolysis|Protein metabolism and modification |
| miR-196a | RIOK3# | RIO kinase 3 (yeast) | 142169 | 3.226 | 0.018 | Protein metabolism and modification|Protein phosphorylation |
| miR-196a | RRAGA | Ras-related GTP binding A | 105497 | 1.243 | 0.023 | G-protein|Small GTPase|Select regulatory molecule |
| miR-196a | ZMYND11 | zinc finger, MYND domain containing 11 | 161540 | 1.665 | 0.036 | Transcription factor|Transcription cofactor |
| miR-128a/miR-196a | CENPE§ | centromere protein E, 312kDa | 165425 | 1.436 | 0.018 | Structural constituent of cytoskeleton |
| miR-142-3p | ZCCHC14 | zinc finger, CCHC domain containing 14 | 200292 | 0.759 | 0.035 | unclassified |
| miR-142-3p | XPO1▲ | exportin 1 (CRM1 homolog, yeast) | 105030 | 0.748 | 0.002 | Intracellular protein transport|IRG▲ |
| miR-142-3p | ATAD2 | ATPase family, AAA domain containing 2 | 114584 | 0.745 | 0.007 | Hydrolase activity |
| miR-142-3p | TRIM33 | tripartite motif-containing 33 | 134526 | 0.714 | 0.004 | Transcription cofactor;Nucleic acid binding|Transcription factor |
| miR-142-3p | RAB1A | RAB1A, member RAS oncogene family | 122650 | 0.704 | 0.045 | G-protein|Small GTPase|Select regulatory molecule |
| miR-142-3p | TFG | TRK-fused gene | 210281 | 0.686 | 0.026 | unclassified |
| miR-142-3p | PMPCB▲ | peptidase (mitochondrial processing) beta | 210046 | 0.684 | 0.015 | Oxidoreductase activity|IRG▲ |
| miR-142-3p | ZNF226 | zinc finger protein 226 | 178824 | 0.682 | 0.043 | Zinc finger transcription factor |
| miR-142-3p | ANKHD1 | ankyrin repeat and KH domain containing 1 | 224628 | 0.658 | 0.006 | unclassified |
| miR-142-3p | CXADR | coxsackie virus and adenovirus receptor | 108284 | 0.620 | 0.025 | Other receptor|Receptor |
| miR-142-3p | CHAF1B# | chromatin assembly factor 1, subunit B (p60) | 174351 | 0.586 | 0.017 | Nucleic acid binding|Chromatin/chromatin-binding protein |
| miR-142-3p | HMGB1▲ | high-mobility group box 1 | 151074 | 0.586 | 0.011 | Proinflammatory cytokine|IRG▲ |
| miR-142-3p | BNIP3 | BCL2/adenovirus E1B 19kDa interacting protein 3 | 109165 | 0.551 | 0.000 | unclassified |
| miR-142-3p | COG4 | component of oligomeric golgi complex 4 | 151150 | 0.394 | 0.042 | Other RNA-binding protein|Nucleic acid binding |
| miR-142-3p | USH1C | Usher syndrome 1C (autosomal recessive, severe) | 195953 | 0.367 | 0.016 | Cytoskeletal protein |
§ Gene targeted by two down-regulated miRs
▲ Interferon regulated gene (IRG) according to the INTERFEROME database
# Gene showing same direction of regulation (up or down) in microarray analysis of HCV genotype 2a chimeric virus J6/JFH infection
Panther classification of Biological processes, Molecular functions and Pathways significantly enriched in the set of 37 genes
| Establishment or maintenance of chromatin architecture | 4 | 0.55 | 2.12E-03 |
| Organelle organization | 4 | 0.59 | 2.85E-03 |
| Intracellular protein transport | 9 | 2.98 | 2.16E-03 |
| Vesicle-mediated transport | 7 | 2.10 | 4.26E-03 |
| Endocytosis | 4 | 1.04 | 1.96E-02 |
| Neurotransmitter secretion | 3 | 0.63 | 2.45E-02 |
| GTPase activity | 3 | 0.52 | 1.53E-02 |
| Peptidase inhibitor activity | 2 | 0.32 | 4.08E-02 |
| Chromatin binding | 2 | 0.34 | 4.59E-02 |
| 2 | 0.13 | 7.19E-03 |
• Number of genes, in the dataset of 37, that map to the indicated Panther classification categories
•• Expected number of genes, in the dataset of 37, based on the NCBI reference list of human genome
••• p-value as determined by the binomial statistic. A cutoff of 0.05 has been applied